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Thromboprophylaxis in pregnant patient-specific risks
Abstract
Background: Pregnancy and the puerperium are well-established risk
factors for venous thromboembolism. Prothrombotic changes start after
conception and normal coagulation returns eight weeks after the labour.
The risk of DVT is approximately twice as high after caesarean delivery
than vaginal birth.
Specific risks: Inherited or acquired thrombophilias increase thrombo-
embolic risk and influence the approach to thromboprophylaxis. Additional
factors that increase thrombotic risk include immobilisation, such as bed
rest for pregnancy complications, surgery including caesarean section, ovar-
ian hyperstimulation during gonadotropin use for in vitro fertilisation,
trauma and malignancy. The preferred agents for thromboprophylaxis in
pregnancy are heparin compounds; these agents do not cross the placenta and
therefore appears safe for the fetus. Because of the theoretical risk of epidural
spinal haemorrhage in women receiving heparin that undergo epidural or
spinal anaesthesia many anaesthesiologist will not perform neuraxial re-
gional anaesthesia in women who have recently received heparin. Anaesthe-
sia guidelines advise waiting to insert the needle at least 10 to 12 hours after
the last prophylactic dose of LMWH, and at least 24 hours after the last
therapeutic dose.
Conclusion: Despite the increased risk of thrombosis in pregnancy, anti-
coagulants are not routinely indicated, because the risks usually outweigh
the benefits. The exception is women on life-long anticoagulation or wo-
men with history of thrombosis or thrombophylia. Heparin therapy must be
interrupted temporarily during the immediate peripartum interval to mi-
nimise the risk of haemorrhage and to allow for the option of regional an-
aesthesia.
INTRODUCTION
Uteroplacental circulation is essential for normal pregnancy develop-ment. The coagulation system undergoes significant changes dur-
ing pregnancy. The clinician caring for the parturient must understand
these changes, particularly when the parturient must has a pre-existing
haematological condition. Prothrombotic changes start after concep-
tion and normal coagulation returns eight weeks after the labour. So,
pregnancy and the puerperium are well-established risk factors for ve-
nous thromboembolism (VTE), which includes deep vein thrombosis
(DVT) and pulmonary embolism (PE). Incidence of VTE is 4 to 50
times higher in pregnant versus non-pregnant women, with absolute
incidence rate of 1 in 500 to 2000 pregnancies. VTE is nearly twice
more often postpartum than antepartum, and DVT is three times more
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mortality from other causes has been reduced and haem-
orrhage is successfully treated or prevented, VTE has
emerged as leading cause of maternal death (2).
The risk of DVT is approximately twice as high after
caesarean delivery than vaginal birth, and DVT is more
common in the left than the right leg. The striking distri-
bution is attributed to increased venous stasis in the left
leg related to compression of the left iliac vein by the
right iliac artery, coupled with compression of the infe-
rior cava by the gravid uterus itself. Pelvic vein DVT is
felt to be more likely in pregnancy, perhaps making diag-
nosis more difficult.
Coagulation disorders in pregnancy
Pregnancy and the postpartum period may be marked
by the presence of all three components of Virchow’s tri-
ad: venous stasis, endothelial injury and a hypercoagul-
able state. Inherited or acquired thrombophilias unre-
lated to pregnancy increase thromboembolic risk and
influence the approach to thromboprophylaxis. Venous
stasis of the lower extremitas occurs because of two factors;
pregnancy-associated changes in venous capacitance and
compression of large veins by the gravid uterus. Although
blood volume and total venous return are supranormal
in pregnancy, the linear flow velocity in the lower ex-
tremity veins is decreased, probably due to hormonal in-
duced dilatation of capacitance veins, which leads to ve-
nous pooling and valvular incompetence. Assuming the
left lateral position significantly increased the velocity in
both lower extremities. Endothelial injury is connected
with delivery, which is associated with vascular injury
and changes at the uteroplacental surface (3). Further-
more, pregnancy is a hypercoagulable state with increas-
ed several coagulation factors; F I, II, VII, VIII, IX and
X, with a lower levels of protein S and increased resis-
tance to activated protein C. Plasminogen activator in-
hibitor type 1 (PAI-1) levels are fivefold increased and
levels of PAI-2, produced by the placenta, dramatically
increase during the third trimester, however total fibrino-
lytic activity may not be impaired (4).
Risk factors for VTE
Inherited thrombophilia is present in 30–50% women
with pregnancy-associated VTE. Pregnant women with
inherited thrombophilias have even more increased risk
for VTE.
The thrombotic risk for women with factor V Leiden
during pregnancy or in puerperium has been estimated
at approximately 1 in 400 to 500 (5). Not only are women
with thrombophilia at a higher risk of thrombosis, they
are more likely to experience placental abruption, pre-
eclampsia, fetal growth restriction, still-birth and possibly
recurrent miscarriage. Factor V Leiden (FVL) is the most
frequently indentified inherited thrombophilia. Throm-
bophilia associated with a high risk of VTE during preg-
nancy include AT deficiency, protein C or S deficiency,
compound heterozygosity for FVL and prothrombin gene
mutation or other combinations of thrombophilia, and
homozygosity for these conditions. Acquired antithrombin
deficiency may also occur in high-proteinuric states such
as nephritic syndrome or preeclampsia, further increas-
ing thrombotic risk.
Additional factors that increase thrombotic risk in-
clude immobilisation, such as bed rest for pregnancy
complications, surgery including caesarean section, ova-
rian hyperstimulation during gonadotropin use for in vi-
tro fertilisation, trauma, malignancy and hereditary or
acquired hypercoagulable states. Other conditions that
increase thrombotic risk include hyperemesis gravidarum,
obesity, inflammatory bowel disease, infection, smooking
and indwelling intravenous catheter (6).
The goal of anticoagulation is not only to prevent and
treat maternal thromboses, but to improve the outcome
of pregnancy. In women with a history of thrombosis and
thrombophilia, anticoagulants have been shown to reduce
maternal morbidity and mortality. In women with the
antiphospholipid syndrome, an aquired thrombophilia
and women with inherited thrombophilia anticoagu-
lants have been shown to increase the probability of a live
birth (7).
Anticoagulants in pregnancy
Anticoagulation in pregnancy requires considera-
tion of both mother and fetus. During pregnancy there
is an increase in blood volume of 40% to 50% and an in-
crease in the volume of distribution. An increase in glo-
merular filtration results in increased renal excretion.
Additionally, there is an increase in protein binding of
heparin. Agents that cross the placenta are potentially
teratogenic.
Warfarin is a vitamin K antagonist. The coagulant ac-
tivity of factors II, VII, IX and X depends of vitamin K.
Treatment with warfarin results in the production of co-
agulation factors with reduced coagulant activity. Warfa-
rin is generally contraindicated during pregnancy. Taken
during the critical period of organogenesis, warfarin car-
ries up to a 30% risk of congenital anomalies. The re-
ported risk of miscarriage ranges from 14.6% to 56%. Pla-
cental transfer of warfarin later in pregnancy can result in
fetal bleeding or stillbirth (8). Long term neurologic
damage has been reported among children exposed in
utero.
UFH (unfractionated heparin) and low-molecular-
weight-heparin (LMWH) exert their anticoagulant ac-
tivity by activating antithrombin. UFH has activity against
both factor Xa and thrombin, whereas LMWH has rela-
tively little activity against thrombin. Heparins, UFH or
LMWH are the preferred agents for anticoagulation in
pregnancy. The main advantage of heparins over other
anticoagulants is that there is no transplacental passage.
Disadvantages of UFH include the necessity of parente-
ral administration, a 2% risk of major bleeding osteopo-
rosis with a 17% to 36% reduction in bone density, a 2%
risk of vertebral fracture and a risk of heparin-induced
thrombocytopenia (HIT) (9).
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Over the last ten years LMWHs have become the pre-
ferred anticoagulants for treating and preventing throm-
boembolism in all patients. LMWHs are fragments of
unfractionated heparin produced by an enzymatic or
chemical depolymerization process with a mean molec-
ular weight of approximately 5000 daltons. Compared
with UFH, LMWHs have relatively greater activity against
factor Xa and are less likely to bind to plasma proteins,
endothelial cells and macrophages. This reduction in
binding increases the bioavailability, half life and antico-
agulant activity of LMWH relative to UFH. Although
parenteral administration is still required, potential ad-
vantages of LMWHs over unfractionated heparin are
less bleeding, less bone loss, a more predictable response,
a lower risk of HIT, a longer half-life and demand less-
intensive monitoring. Like UFH there is no transplacen-
tal passage. The physiologic changes of pregnancy alter
the metabolism of LMWH, resulting in lower peak levels
and a higher rate of clearance, and so pregnant women
may need higher doses or more frequent dosing.
Fondaparinux, a selective inhibitor of factor Xa, is a
pentasaccharide that mimics the active site of heparin
that binds to antithrombin. Fondaparinux is administred
subcutaneously. In in vitro models, there was no placen-
tal transfer. Fondaparinux may be the preferred alterna-
tive to heparins in the case of heparin allergy or HIT in
pregnancy (7).
Aspirin is an antiplatelet drug rather than an antico-
agulant. Low dose aspirin (81 mg per day) has been ex-
tensively evaluated during pregnancy and has been shown
to be safe and effective in reducing the risk of preeclampsia
in high risk women, and in women with antiphospho-
lipid antibodies and recurrent pregnancy loss. Large,
randomised trials have demonstrated no increased risk of
miscarriage, congenital anomalies, placental abruption,
fetal haemorrhage or neonatal bleeding. In women with
either mechanical heart valves or in antiphospholipid
syndrome, low-dose aspirin may be used in combination
with heparins (10).
Women with history of myocardial infarction, with risk
factors for arterial thrombosis and mechanical heart valves
use other antiplatelet agents for supplemental therapy.
There are no data for placental transfer of dipyridamole,
clopidogrel and ticlopiridine.
Thrombolysis is indicated for life threatening thrombo-
embolism. There are recent reports of its use in pregnancy
to treat pulmonary embolism, coronary artery thrombo-
sis, massive deep vein thrombosis, cerebral vein throm-
bosis and mechanical valve thrombosis. Thrombolytic
agents such as urokinase, streptokinase and recombinant
tissue plasminogen activator do not cross the placenta,
but can potentially jeopardize the fetus if bleeding occurs
in the retroplacental space. The risk of fetal loss has been
estimated to be 5.8% and the risk of maternal mortality to
be 1.2%.
Women of lifelong anticoagulation may be converted
from warfarin to LMWH before pregnancy or as soon as
possible after conception. Although the use of pneumatic
compression devices for the prevention of peripartum
thrombosis has not been studied, extrapolation from peri-
operative data would suggest benefit. The devices may be
placed in labor after epidural administration or before
caesarean delivery.
Guidelines have been developed for antithrombotic
therapy during pregnancy. These recommendations are
usually consensus, rather than evidence-based and in-
volve assessing VTE risk. Heparin prophylaxis is recom-
mended for those in higher-risk categories. As 50% of
VTE occurs postpartum, these guidelines recommend
heparin or warfarin for 6 weeks postpartum in women with
history of VTE or thrombophilia. VTE during preg-
nancy is treated with therapeutic heparin.
Neuraxial anaesthesia
There is considerable debate about administering ne-
uraxial anaesthesia in parturient with thrombocytope-
nia. A platelet count from 70 ´ 109/L to 100 ´ 109/L in
otherwise healthy parturient should not contraindicate
regional anaesthesia. Most American anaesthesiologist
would insert an epidural in a healthy parturient with
platelet count 80 ´ 109/L. The situation is more contro-
versial in the setting of preeclampsia, including HELLP
syndrome. In this situation, most anaesthesiologist con-
siders the platelet count, the clinical picture and whether
the thrombocytopenia is stable or decreasing.
Heparin therapy should be temporarily stopped dur-
ing the immediate peripartum interval to minimise the
risk of haemorrhage and to permit regional anaesthesia.
Because of the theoretical risk of epidural spinal haemor-
rhage in women receiving heparin that undergo epidural
or spinal anaesthesia many anaesthesiologist will not
perform neuraxial regional anaesthesia in women who
have recently received heparin. Since UFH has a rela-
tively short duration of action, the American Society of
Regional Anaesthesia states that subcutaneous UFH pro-
phylaxis is not a contraindication to neuraxial regional
anaesthesia. However, LMWHs should be stopped for at
least 12 to 24 hours before regional anaesthesia can be
considered safe (11).
Anaesthesia guidelines advise waiting to insert the
needle at least 10 to 12 hours after the last prophylactic
dose of LMWH, and at least 24 hours after the last thera-
peutic dose. To facilitate use of regional anaesthesia in
pregnant women on heparin, it’s useful to electively stop
LMWH 24 hours before planning induction of labour or
electively stop prophylactic-dose LMWH or UFH at
about 38 weeks of gestation to await spontaneous labour.
Therefore, pragmatically is to switch therapeutic or pro-
phylactic LMWH to UFH at about 36 weeks of gesta-
tion, with instructions to discontinue the injections in
the earliest stages of spontaneous labour. This aims to
shorten the heparin-free period required before neu-
raxial anaesthesia while minimizing maternal throm-
botic risk.
Additional advantages to using UFH peripartum inclu-
de the ability to completely reverse the heparin effect with
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protamine sulphate if major bleeding occurs. LMWHs
are only partially reversible.
Anaesthesiologists are commonly asked to provide
epidural anaesthesia for labour and/or delivery in women
using prophylactic heparin. There is justifiable concern
about administering neuraxial anaesthesia in woman on
heparin due to risk of a neuraxial haematoma. Neuraxial
anaesthesia is contraindicated when a women is on ther-
apeutic heparin. Consensus-based recommendations re-
garding neuraxial anaesthesia in patients on antithrom-
botics have been developed (12).
Epidural spinal haemathoma are the most common
type of spinal haemathoma, followed by subarachnoid
haemathomas. Anticoagulants and antithrombotic drugs
can increase the risk of spinal haemathoma formation,
especially following neuraxial blockade. Neuraxial anaes-
thetic practice guidelines have been developed and re-
vised to minimize the risk of spinal haemathoma in pa-
tients receiving LMWH as well as other newer anticoag-
ulants (13, 14).
CONCLUSION
Despite the increased risk of thrombosis in pregnancy,
anticoagulants are not routinely indicated, because the
risks usually outweigh the benefits. The exception is
women on life-long anticoagulation or women with his-
tory of thrombosis or thrombophylia. Heparin therapy
must be interrupted temporarily during the immediate
peripartum interval to minimise the risk of haemorrhage
and to allow for the option of regional anaesthesia.
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